[1]刘亚萍 卢燕 张艺文 张全波 汪汉.肠道菌群及其代谢物与非酒精性脂肪性肝病[J].心血管病学进展,2023,(12):1130.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.017]
　LIU Yaping,LU Yan,ZHANG Yiwen,et al.Intestinal Flora and Its Metabolites and?onalcoholic Fatty Liver Disease[J].Advances in Cardiovascular Diseases,2023,(12):1130.[doi:10.16806/j.cnki.issn.1004-3934.2023.12.017]
点击复制

肠道菌群及其代谢物与非酒精性脂肪性肝病()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年12期
页码:
1130
栏目:
综述
出版日期:
2023-12-25

文章信息/Info

Title:
Intestinal Flora and Its Metabolites and?onalcoholic Fatty Liver Disease
作者:
刘亚萍1; 2 卢燕1; 2 张艺文2 张全波1; 2 汪汉1; 2
(1.川北医学院,四川 南充 637000;2.西南交通大学附属医院 成都市第三人民医院心内科 成都市心血管病研究所,四川 成都 610031)
Author(s):
LIU Yaping1; 2; LU Yan1; 2; ZHANG Yiwen2; ZHANG Quanbo1; 2; WANG Han1; 2
?1.North Sichuan Medical College,Nanchong 637000,Sichuan,China;2.Department of Cardiology,The Affiliated Hospital of Southwest Jiaotong University,The Third People’s Hospital of Chengdu,Cardiovascular Disease Research Institute of Chengdu,Chengdu 610031,Sichuan,China)
关键词:
肠道菌群; 肠道代谢物; 肠肝轴; 非酒精性脂肪性肝病
Keywords:
Intestinal flora; Intestinal metabolite; Gut-liver axis; Non-alcoholic fatty liver disease
DOI:
10.16806/j.cnki.issn.1004-3934.2023.12.017
摘要:
总结相关的实验研究发现，人体肠道菌群是非酒精性脂肪性肝病（NAFLD）发生发展的关键因素，除了人体肠道菌群组成的变化外，肠道菌群的代谢物也成为调节NAFLD病理过程的关键因素；有研究发现，肠道菌群的代谢物如短链脂肪酸、胆汁酸、三甲胺和乙醇等通过肠-肝轴途径影响肝脏代谢功能，从而导致疾病发生。现从NAFLD患者肠道菌群和代谢物的变化及发病机制，总结并探讨通过调节肠道菌群及其代谢物来治疗NAFLD，期望这些治疗策略会成为未来优化治疗NAFLD等代谢性肝病的有效方法。
Abstract:
Summary of relevant experimental studies found that the human intestinal flora is a key factor in the development of non-alcoholic fatty liver disease (NAFLD). In addition to changes in the composition of human intestinal flora,the metabolites of intestinal flora also become the key factors regulating the pathological process of NAFLD. Some studies have found that metabolites of intestinal flora such as short-chain fatty acids,bile acids,trimethylamine and ethanol affect liver metabolic function through the gut-liver axis pathway,thus leading to disease. Based on the changes and pathogenesis of intestinal flora and metabolites in patients with NAFLD,this paper summarizes and discusses the treatment of NAFLD by regulating intestinal flora and metabolites,hoping that these therapeutic strategies will become effective ways to optimize the treatment of metabolic liver diseases such as NAFLD in the future

参考文献/References:

[1]Fabbrini E,Magkos F. Hepatic steatosis as a marker of metabolic dysfunction[J]. Nutrients,2015,7(6):4995-5019.

[2]Younossi ZM,Koenig AB,Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.
[3]Eslam M,Newsome PN,Sarin SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:an international expert consensus statement[J]. J Hepatol,2020,73(1):202-209.?/div>
[4]Romeo S. Notch and nonalcoholic fatty liver and fibrosis[J]. N Engl J Med,2019 Feb 14;380(7):681-683.?/div>
?5]Friedman SL,Neuschwander-Tetri BA,Rinella M,et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med,2018,24(7):908-922.
?6]Thursby E,Juge N. Introduction to the human gut microbiota[J]. Biochem J,2017,474(11):1823-1836.
[7]Rinninella E,Raoul P,Cintoni M,et al. What is the healthy gut microbiota composition? A changing ecosystem across age,environment,diet,and diseases[J]. Microorganisms,2019,7(1):14.
[8]Quesada-Vázquez S,Bone C,Saha S,et al. Microbiota dysbiosis and gut barrier dysfunction associated with non-alcoholic fatty liver disease are modulated by a specific metabolic cofactors’ combination[J]. Int J Mol Sci,2022,23(22):13675.?/div>
[9]Albillos A,de Gottardi A,Rescigno M. The gut-liver axis in liver disease:Pathophysiological basis for therapy[J]. J Hepatol,2020,72(3):558-577.
[10]Hu H,Lin A,Kong M,et al. Intestinal microbiome and NAFLD:molecular insights and therapeutic perspectives[J].? Gastroenterol,2020,55:142-158.
?11]Wang B,Jiang X,Cao M,et al. Altered Fecal Microbiota Correlates With Liver Biochemistry In Nonobese Patients With Non-Alcoholic Fatty Liver Disease[J].?ci Rep,2016,6:32002.
[12]Li F,Ye J,Shao C,et al. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients:a systematic review and meta-analysis[J]. Lipids Health Dis,2021,20(1):22.
[13]Del Chierico F,Nobili V,Vernocchi P,et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach[J].?epatology,2017,65:451-464.
[14]Aron-Wisnewsky J,Vigliotti C,Witjes J,et al. Gut microbiota and human NAFLD:disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol,2020,17(5):279-297.
[15]Luo W,Ye L,Hu XT,et al. MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease[J]. Clin Transl Med,2022,12(3):e777. [16]Parthasarathy G,Revelo X,Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis:an overview[J].?epatol Commun,2020,4(4):478-492.
[17]Ferro D,Baratta F,Pastori D,et al. New insights into the pathogenesis of non-alcoholic fatty liver disease:gut-derived lipopolysaccharides and oxidative stress[J]. Nutrients,2020,12(9):2762.
[18]Arab JP,Karpen SJ,Dawson PA,et al. Bile acids and nonalcoholic fatty liver disease:molecular insights and therapeutic perspectives[J]. Hepatology,2017,65(1):350-362.
[19]Xu J,Lai KKY,Verlinsky A,et al. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK[J]. J Hepatol,2011,55(3):673-682.
[20]den Besten G,van Eunen K,Groen AK,et al. The role of short-chain fatty acids in the interplay between diet,gut microbiota,and host energy metabolism[J]. J Lipid Res,2013,54(9):2325-2340.
[21]Baxter NT,Schmidt AW,Venkataraman A,et al. Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers[J]. mBio,2019,10(1):e02566-18.

相似文献/References:

[1]杨娟,综述,王佑华,等.肠道菌群与血管内炎症[J].心血管病学进展,2016,(3):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
　YANG Juan,WANG Youhua,YUAN Suyun.Relationship Between Gut Microbiota and Vascular Inflammation[J].Advances in Cardiovascular Diseases,2016,(12):263.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.012]
[2]张琪 宋晓鹏 任茂佳 吴广 赵兴胜.氧化三甲胺与心血管疾病的研究新进展[J].心血管病学进展,2020,(1):81.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.022]
　ZHANG Qi,SONG Xiaopeng,REN Maojia,et al.Trimethylamine Oxide and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(12):81.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.022]
[3]李靖,任彭,努尔比耶·买买提,等.三甲胺-N-氧化物与冠心病和心力衰竭的研究进展[J].心血管病学进展,2020,(3):272.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.014]
　LI Jing,REN Peng,Nuerbiye·Maimaiti,et al.Trimethylamine-N-oxide and Coronary Heart Disease and Heart Failure[J].Advances in Cardiovascular Diseases,2020,(12):272.[doi:10.16806/j.cnki.issn.1004-3934.2019.00.014]
[4]王猛 江洪.肠道菌群及其代谢产物与心房颤动的研究进展[J].心血管病学进展,2022,(3):214.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
　WANG Meng,JIANG Hong.Gut Microbiota an d Its Metabolites in Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(12):214.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[5].肠-脑轴与心血管疾病的研究进展[J].心血管病学进展,2022,(7):595.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
　TAN Wuping,W ANG Meng,ZHOU Xiaoya.Gut-Brain Axis and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(12):595.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[6]刘杏利 高中山 段豪亮 赵奕 马玉兰.肠道菌群及其代谢物与心律失常关系的研究进展[J].心血管病学进展,2022,(11):1002.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.009]
　LIU Xingli,GAO Zhongshan,DUAN Haoliang,et al.The Relationship Between Intestinal Flora and Its Metabolites and Arrhythmia[J].Advances in Cardiovascular Diseases,2022,(12):1002.[doi:10.16806/j.cnki.issn.1004-3934.2022.11.009]
[7]张嘉原 张莉.果糖代谢与血脂异常的研究进展[J].心血管病学进展,2022,(12):1114.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.013]
　ZHANG Jiayuan ZHANG Li.Fructose Metabolism and DyslipidemiaA Systematic Review[J].Advances in Cardiovascular Diseases,2022,(12):1114.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.013]
[8]卢燕 刘亚萍 罗强 张全波 汪汉.肠道菌群及其代谢物与痛风[J].心血管病学进展,2023,(2):177.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.018]
　LU Yan,LIU Yaping,LUO Qiang,et al.Intestinal Flora and Its Metabolites and Gout[J].Advances in Cardiovascular Diseases,2023,(12):177.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.018]
[9]蒋振江 刘富强 王军奎.肠道菌群与肥胖的关系研究进展[J].心血管病学进展,2023,(3):265.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.017]
　JIANG Zhenjiang,LIU Fuqiang,WANG Junkui.The Relationship Between Gut Microbiota and Obesity[J].Advances in Cardiovascular Diseases,2023,(12):265.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.017]
[10]李帅 刘富强 王军奎.酒精摄入对肠道菌群的影响及其机制研究进展[J].心血管病学进展,2023,(2):172.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.017]
　LI ShuaiLIU FuqiangWANG Junkui.Effects of Alcohol Intake on Intestinal Flora and Its Mechanism[J].Advances in Cardiovascular Diseases,2023,(12):172.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.017]

备注/Memo

备注/Memo:
收稿日期：2023-03-05基金项目: 四川省中医药管理局2020JC0010）; 成都市卫健委医学科研课题2021206）
更新日期/Last Update: 2024-01-19